Download PDF

1. Company Snapshot

1.a. Company Description

Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide.The company's Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures.It's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions.


In addition, its Precision Motion segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles.The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands.The company was formerly known as GSI Group, Inc.


and changed its name to Novanta Inc.in May 2016.Novanta Inc.


was founded in 1968 and is headquartered in Bedford, Massachusetts.

Show Full description

1.b. Last Insights on NOVT

Novanta Inc.'s recent performance was driven by a series of positive developments. The company's impressive earnings surprise history, coupled with its strong financials, suggests a high likelihood of beating estimates in its next quarterly report. Additionally, institutional investors have been increasing their stakes in the company, with American Capital Management doubling down on Novanta stock and Bradley Foster & Sargent Inc. CT increasing its stake by 10.0% in the third quarter. Furthermore, the company's CEO, Matthijs Glastra, sold 7,500 shares of the business's stock, but this sale is not indicative of a negative trend.

1.c. Company Highlights

2. Novanta's Record Q4 2025: Strong Bookings and Revenue Growth

Novanta Inc. reported a record revenue of $281 million in Q4 2025, with a 9% year-over-year growth and 4% sequential growth. The company's adjusted gross margin was 45.5%, and adjusted EBITDA was $61 million, up 17% year-over-year. Non-GAAP adjusted EPS was $0.91, beating the estimate of $0.88, however actual EPS came out at $0.4517. For the full year, revenue hit a record $981 million, with bookings growing 14% year-over-year.

Publication Date: Mar -01

📋 Highlights
  • Record Full-Year Revenue:: Achieved $981 million in 2025, with 9% YoY growth and 4% sequential growth in Q4.
  • Surge in Bookings:: Bookings rose 25% YoY and 12% sequentially, with a book-to-bill ratio of 1.11.
  • Profit Growth:: Adjusted EBITDA grew 17% to $61 million, and adjusted EPS increased 20% to $0.91.
  • Strong Acquisition Position:: Secured $600 million in financing, enabling $1.5 billion in acquisition capacity for strategic growth.
  • Positive Net Cash Position:: Net debt turned negative $121 million, marking the first positive cash position in over a decade.

Segment Performance

The Automation Enabling Technologies segment saw a 2% sequential growth, driven by demand for advanced robotic applications and increasing strength in semiconductor applications. New product revenue grew over 80% year-over-year in the quarter and nearly 90% for the full year. The Medical Solutions segment grew 16% year-over-year, with a book-to-bill of 1.07 in the fourth quarter and bookings up 17% year-over-year.

Outlook and Guidance

Novanta expects mid-single-digit organic growth in 2026, driven by record bookings, new product launches, and commercial momentum. The company guides for 2026 gross margin expansion of approximately 100 basis points and operating cash flow of $145-185 million. For 2026, the company expects GAAP revenue to be approximately $1,030 million to $1,050 million, representing 4% to 6% organic revenue growth.

Valuation and Growth Expectations

With a P/E Ratio of 95.49 and an EV/EBITDA of 28.75, the market is pricing in high growth expectations. Analysts estimate next year's revenue growth at 6.6%. The company's EPS growth expectation of 9% at the midpoint is largely due to a $0.22 to $0.24 headwind from the recent fundraise and a $0.14 headwind from an all-employee grant. The organic element of the EPS growth is significantly higher than 9%.

Acquisition Strategy and Pipeline

Novanta raised over $600 million in November to deploy into acquisitions, with a $1.5 billion acquisition capacity. The company is focused on M&A in the medical space, particularly in areas such as medical consumables and embedded software. The acquisition of Keyon contributed $9 million of incremental revenue in the first quarter, with a mix of project-based business and recurring revenue stream.

3. NewsRoom

Card image cap

Blair William & Co. IL Decreases Stock Holdings in Novanta Inc. $NOVT

Mar -09

Source: defenseworld.net

Card image cap

Novanta Stock Has Underperformed This Past Year, but One Investor Just Made a $36 Million Bet on Shares

Mar -04

Source: fool.com

Card image cap

Is Novanta Stock a Buy or Sell After Its CEO Dumped 7,500 Shares Worth $1.1 Million?

Feb -26

Source: fool.com

Card image cap

Bradley Foster & Sargent Inc. CT Increases Stake in Novanta Inc. $NOVT

Feb -26

Source: defenseworld.net

Card image cap

Novanta Inc. (NOVT) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

Card image cap

Is Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?

Feb -22

Source: fool.com

Card image cap

Will Novanta (NOVT) Beat Estimates Again in Its Next Earnings Report?

Feb -20

Source: zacks.com

Card image cap

American Capital Management Doubles Down on Novanta Stock, According to Latest SEC Filing

Feb -20

Source: fool.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.33%)

6. Segments

Medical Solutions

Expected Growth: 9%

Novanta's Medical Solutions segment growth is driven by increasing demand for minimally invasive surgical procedures, advancements in robotics and digitalization, and a growing need for precision medical components. Additionally, the segment benefits from strategic acquisitions, expanding into new markets, and a strong reputation for quality and innovation.

Precision Medicine and Manufacturing

Expected Growth: 11%

Novanta's Precision Medicine and Manufacturing segment growth is driven by increasing demand for personalized medicine, advancements in gene editing and gene therapy, and adoption of robotics and automation in manufacturing. Additionally, the segment benefits from growing investments in research and development, and strategic acquisitions that expand its product portfolio and geographic reach.

Robotics and Automation

Expected Growth: 8%

Novanta's Robotics and Automation segment growth is driven by increasing demand for precision motion and vision technologies in industries such as medical, industrial, and semiconductor manufacturing. The trend towards Industry 4.0 and smart factories also fuels growth, as companies invest in automation and robotics to improve efficiency and productivity.

7. Detailed Products

Laser Systems

Novanta's laser systems provide high-precision laser processing solutions for various industries, including semiconductor, microelectronics, and industrial manufacturing.

Photonics Solutions

Novanta's photonics solutions offer a range of optical components, modules, and subsystems for applications in telecommunications, data centers, and industrial manufacturing.

Vision Systems

Novanta's vision systems provide machine vision solutions for inspection, measurement, and automation in industries such as semiconductor, electronics, and medical devices.

Precision Motion Systems

Novanta's precision motion systems offer high-precision motion control solutions for industries such as semiconductor, medical devices, and industrial manufacturing.

Medical Technologies

Novanta's medical technologies provide innovative solutions for medical device manufacturing, including precision motion, vision, and laser systems.

8. Novanta Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Novanta Inc. operates in a niche market with specialized products, reducing the threat of substitutes. However, the company's reliance on a few key customers increases the risk of substitution.

Bargaining Power Of Customers

Novanta Inc.'s customers, including medical device manufacturers and industrial companies, have significant bargaining power due to their large size and negotiating power.

Bargaining Power Of Suppliers

Novanta Inc. has a diversified supplier base, reducing the bargaining power of individual suppliers. The company's strong relationships with suppliers also mitigate the risk of supply chain disruptions.

Threat Of New Entrants

The medical technology and industrial technology markets served by Novanta Inc. have high barriers to entry, including significant capital requirements and regulatory hurdles, reducing the threat of new entrants.

Intensity Of Rivalry

The markets served by Novanta Inc. are moderately competitive, with a few established players competing for market share. However, the company's specialized products and strong customer relationships help to mitigate the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 35.04%
Debt Cost 7.33%
Equity Weight 64.96%
Equity Cost 10.66%
WACC 9.49%
Leverage 53.94%

11. Quality Control: Novanta Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Trimble

A-Score: 4.7/10

Value: 1.3

Growth: 5.2

Quality: 6.9

Yield: 0.0

Momentum: 7.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
MKS Instruments

A-Score: 4.6/10

Value: 3.4

Growth: 5.0

Quality: 6.9

Yield: 1.0

Momentum: 8.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Itron

A-Score: 4.5/10

Value: 5.4

Growth: 5.8

Quality: 7.1

Yield: 0.0

Momentum: 3.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Cognex

A-Score: 3.7/10

Value: 1.2

Growth: 2.8

Quality: 7.6

Yield: 1.0

Momentum: 5.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Coherent

A-Score: 3.4/10

Value: 0.8

Growth: 4.9

Quality: 4.4

Yield: 0.0

Momentum: 8.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Novanta

A-Score: 3.3/10

Value: 1.2

Growth: 7.0

Quality: 5.5

Yield: 0.0

Momentum: 2.0

Volatility: 4.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

123.14$

Current Price

123.14$

Potential

-0.00%

Expected Cash-Flows